SUPPLEMENT

Q2 2026 — Financial disclosures

Q2 2026PDF · 10 pages1.1 MB
Merck & Co., Inc.,
Rahway, N.J., USA
Financial Highlights Package
Second Quarter 2026
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 2Q26 and June YTD 26.......3
Table 2b: GAAP to Non-GAAP Reconciliation 2Q25 and June YTD 25.......4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / International 2Q26.................................................6
Table 3b: Sales – U.S. / International June YTD 26.....................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	16,607	$ 	15,806	$ 	5% 	32,893	$ 	31,335	$ 	5%
Costs, Expenses and Other
Cost of sales 	4,395 	3,557 	24% 	8,590 	6,976 	23%
Selling, general and administrative 	2,904 	2,649 	10% 	5,604 	5,202 	8%
Research and development 	9,741 	4,048 	* 	22,333 	7,669 	*
Restructuring costs 	151 	560 	-73% 	346 	629 	-45%
Other (income) expense, net 	99 	(7) 	* 	237 	(43) 	*
(Loss) Income Before Taxes 	(683) 	4,999 	* 	(4,217) 	10,902 	*
Income Tax Provision 	654 	571 	1,363 	1,388
Net (Loss) Income 	(1,337) 	4,428 	* 	(5,580) 	9,514 	*
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(2) 	1 	(5) 	8
Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	(1,335)	$ 	4,427	$ 	* 	(5,575)	$ 	9,506	$ 	*
(Loss) Earnings per Common Share Assuming Dilution (1) 	(0.54)	$ 	1.76	$ 	* 	(2.26)	$ 	3.77	$ 	*
Average Shares Outstanding Assuming Dilution (1) 	2,470 	2,513 	2,471 	2,522
Tax Rate 	-95.9% 	11.4% 	-32.3% 	12.7%
* 100% or greater
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
(1) Because the Company recorded a net loss in both the second quarter and first six months of 2026, no potential dilutive common shares were used in the computations of loss per
common share assuming dilution as the effects would have been anti-dilutive.
GAAP
% Change	June YTD
2026
June YTD
2025
GAAP
% Change
2Q26 	2Q25
1

-- 2 of 10 --

Sales 	16,286	$ 	16,607	$ 	32,893	$ 	15,529	$ 	15,806	$ 	31,335	$ 	17,276	$ 	16,400	$ 	65,011	$ 	5% 	5%
Costs, Expenses and Other
Cost of sales 	4,195 	4,395 	8,590 	3,419 	3,557 	6,976 	3,855 	5,551 	16,382 	24% 	23%
Selling, general and administrative 	2,700 	2,904 	5,604 	2,552 	2,649 	5,202 	2,633 	2,898 	10,733 	10% 	8%
Research and development 	12,592 	9,741 	22,333 	3,621 	4,048 	7,669 	4,234 	3,886 	15,789 	* 	*
Restructuring costs 	195 	151 	346 	69 	560 	629 	47 	213 	889 	-73% 	-45%
Other (income) expense, net 	138 	99 	237 	(35) 	(7) 	(43) 	(238) 	432 	151 	* 	*
(Loss) Income Before Taxes 	(3,534) 	(683) 	(4,217) 	5,903 	4,999 	10,902 	6,745 	3,420 	21,067 	* 	*
Income Tax Provision 	709 	654 	1,363 	818 	571 	1,388 	958 	458 	2,804
Net (Loss) Income 	(4,243) 	(1,337) 	(5,580) 	5,085 	4,428 	9,514 	5,787 	2,962 	18,263 	* 	*
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(3) 	(2) 	(5) 	6 	1 	8 	2 	(1) 	9
Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	(4,240)	$ 	(1,335)	$ 	(5,575)	$ 	5,079	$ 	4,427	$ 	9,506	$ 	5,785	$ 	2,963	$ 	18,254	$ 	* 	*
(Loss) Earnings per Common Share Assuming Dilution (1) 	(1.72)	$ 	(0.54)	$ 	(2.26)	$ 	2.01	$ 	1.76	$ 	3.77	$ 	2.32	$ 	1.19	$ 	7.28	$ 	* 	*
Average Shares Outstanding Assuming Dilution (1) 	2,472 	2,470 	2,471 	2,531 	2,513 	2,522 	2,498 	2,488 	2,507
Tax Rate 	-20.1% 	-95.9% 	-32.3% 	13.9% 	11.4% 	12.7% 	14.2% 	13.4% 	13.3%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Because the Company recorded a net loss in both the second quarter and first six months of 2026, no potential dilutive common shares were used in the computations of loss per common share assuming dilution as the effects
would have been anti-dilutive.
% Change
4Q 	2Q 	Full Year	Full Year
2026
2Q	1Q 	1Q 	2Q 	3Q
2025
June YTD 	June YTD
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
2

-- 3 of 10 --

Second Quarter
Cost of sales 	4,395	$ 	1,067 	184 	1,251 	3,144	$
Selling, general and administrative 	2,904 	17 	17 	2,887
Research and development 	9,741 	6 	(1) 	5 	9,736
Restructuring costs 	151 	151 	151 	–
Other (income) expense, net 	99 	(191) 	(191) 	290
Loss Before Taxes 	(683) 	(1,090) 	(334) 	191 	(1,233) 	550
Income Tax Provision (Benefit) 	654 	(219) (3) 	(50) (3) 	41 (3) 	(228) 	882
Net Loss 	(1,337) 	(871) 	(284) 	150 	(1,005) 	(332)
Net Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA 	(1,335) 	(871) 	(284) 	150 	(1,005) 	(330)
Loss per Common Share Assuming Dilution (4) 	(0.54)	$ 	(0.35) 	(0.12) 	0.06 	(0.41) 	(0.13)	$
Tax Rate 	-95.9% 	160.3%
June YTD
Cost of sales 	8,590	$ 	2,081 	421 	2,502 	6,088	$
Selling, general and administrative 	5,604 	49 	49 	5,555
Research and development 	22,333 	6 	33 	39 	22,294
Restructuring costs 	346 	346 	346 	–
Other (income) expense, net 	237 	(371) 	(371) 	608
Loss Before Taxes 	(4,217) 	(2,136) 	(800) 	371 	(2,565) 	(1,652)
Income Tax Provision (Benefit) 	1,363 	(421) (3) 	(135) (3) 	80 (3) 	(476) 	1,839
Net Loss 	(5,580) 	(1,715) 	(665) 	291 	(2,089) 	(3,491)
Net Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA 	(5,575) 	(1,715) 	(665) 	291 	(2,089) 	(3,486)
Loss per Common Share Assuming Dilution (4) 	(2.26)	$ 	(0.70) 	(0.27) 	0.12 	(0.85) 	(1.41)	$
Tax Rate 	-32.3% 	-111.3%
Only the line items that are affected by non-GAAP adjustments are shown.
(4) Because the Company recorded a net loss in both the second quarter and first six months of 2026, no potential dilutive common shares were used in the computations of loss per common share assuming
dilution as the effects would have been anti-dilutive.
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends.
Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management
uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior
management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP.
(1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets, as well as the recognition of fair value step-up of inventories related to the 2025 Verona Pharma plc acquisition.
Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested, as well as contractual termination costs,
associated with activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
MERCK & CO., INC., RAHWAY, N.J., USA
THREE AND SIX MONTHS ENDED JUNE 30, 2026 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
GAAP 	Acquisition- and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal 	Non-GAAP
3

-- 4 of 10 --

Second Quarter
Cost of sales 	3,557	$ 	576 	165 	741 	2,816	$
Selling, general and administrative 	2,649 	15 	1 	16 	2,633
Research and development 	4,048 	3 	53 	56 	3,992
Restructuring costs 	560 	560 	560 	–
Other (income) expense, net 	(7) 	(61) 	(61) 	54
Income Before Taxes 	4,999 	(594) 	(779) 	61 	(1,312) 	6,311
Income Tax Provision (Benefit) 	571 	(102) (3) 	(139) (3) 	14 (3) 	(146) (4) 	(373) 	944
Net Income 	4,428 	(492) 	(640) 	47 	146 	(939) 	5,367
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	4,427 	(492) 	(640) 	47 	146 	(939) 	5,366
Earnings per Common Share Assuming Dilution 	1.76	$ 	(0.20) 	(0.25) 	0.02 	0.06 	(0.37) 	2.13	$
Tax Rate 	11.4% 	15.0%
June YTD
Cost of sales 	6,976	$ 	1,196 	201 	1,397 	5,579	$
Selling, general and administrative 	5,202 	38 	1 	39 	5,163
Research and development 	7,669 	10 	53 	63 	7,606
Restructuring costs 	629 	629 	629 	–
Other (income) expense, net 	(43) 	(3) 	(168) 	(171) 	128
Income Before Taxes 	10,902 	(1,241) 	(884) 	168 	(1,957) 	12,859
Income Tax Provision (Benefit) 	1,388 	(219) (3) 	(157) (3) 	36 (3) 	(146) (4) 	(486) 	1,874
Net Income 	9,514 	(1,022) 	(727) 	132 	146 	(1,471) 	10,985
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	9,506 	(1,022) 	(727) 	132 	146 	(1,471) 	10,977
Earnings per Common Share Assuming Dilution 	3.77	$ 	(0.40) 	(0.29) 	0.05 	0.06 	(0.58) 	4.35	$
Tax Rate 	12.7% 	14.6%
Only the line items that are affected by non-GAAP adjustments are shown.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Represents tax benefits primarily resulting from favorable audit reserve adjustments.
Non-GAAP
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures
internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in
part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets and intangible asset impairment charges, partially offset by a decrease in the estimated fair value measurement of liabilities for contingent
consideration. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development
expenses reflect the amortization of intangible assets.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the Company's formal restructuring programs.
GAAP
Acquisition- and
Divestiture-Related Costs	
(1)	
Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Certain Other Items 	Adjustment
Subtotal
MERCK & CO., INC., RAHWAY, N.J., USA
THREE AND SIX MONTHS ENDED JUNE 30, 2025 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
4

-- 5 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2026 	2025 	2Q 	June YTD
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$16,286 	$16,607 	$32,893 	$15,529 	$15,806 	$31,335 	$17,276 	$16,400 	$65,011 	5 	4 	5 	3
PHARMACEUTICAL 	14,349 	14,760 	29,109 	13,638 	14,050 	27,688 	15,611 	14,843 	58,142 	5 	4 	5 	3
Oncology
Keytruda 	7,906 	7,904 	15,810 	7,205 	7,956 	15,161 	8,142 	8,337 	31,641 	-1 	-2 	4 	2
Keytruda Qlex 	128 	463 	590 	5 	35 	40 	- 	- 	- 	-
Alliance Revenue – Lynparza (2) 	341 	365 	706 	312 	370 	682 	379 	389 	1,450 	-1 	-2 	4 	2
Alliance Revenue – Lenvima (2) 	256 	283 	539 	258 	265 	523 	258 	272 	1,053 	7 	6 	3 	2
Welireg 	199 	271 	470 	137 	162 	300 	196 	220 	716 	67 	67 	57 	56
Alliance Revenue – Reblozyl (3) 	148 	122 	270 	119 	107 	226 	136 	164 	525 	15 	15 	20 	20
Vaccines (4)
Gardasil/Gardasil 9 	1,069 	1,169 	2,238 	1,327 	1,126 	2,453 	1,749 	1,031 	5,233 	4 	3 	-9 	-10
ProQuad/M-M-R II/Varivax 	538 	592 	1,130 	539 	609 	1,148 	684 	619 	2,451 	-3 	-3 	-2 	-3
Vaxneuvance 	202 	148 	350 	230 	229 	459 	226 	140 	825 	-35 	-36 	-24 	-26
RotaTeq 	206 	134 	340 	228 	121 	349 	204 	119 	673 	10 	9 	-3 	-4
Capvaxive 	142 	184 	325 	107 	129 	236 	244 	279 	759 	42 	40 	38 	36
Enflonsia 	1 	2 	3 	79 	21 	100 	- 	- 	- 	-
Cardiometabolic & Respiratory
Winrevair 	525 	588 	1,114 	280 	336 	615 	360 	467 	1,443 	75 	75 	81 	81
Ohtuvayre 	131 	204 	335 	178 	178 	- 	- 	- 	-
Alliance Revenue - Adempas/Verquvo (5 	109 	126 	235 	106 	123 	229 	112 	129 	470 	3 	3 	3 	3
Adempas (6) 	78 	78 	156 	68 	80 	147 	82 	83 	312 	-2 	-4 	6 	1
Infectious Diseases
Bridion 	472 	497 	969 	441 	461 	902 	439 	499 	1,841 	8 	8 	7 	7
Prevymis 	272 	295 	568 	208 	228 	436 	266 	275 	978 	29 	28 	30 	27
Delstrigo 	75 	101 	176 	67 	83 	150 	77 	79 	306 	21 	17 	17 	10
Zerbaxa 	82 	77 	159 	70 	74 	145 	81 	87 	312 	4 	2 	10 	8
Isentress/Isentress HD 	59 	60 	119 	90 	86 	176 	82 	67 	325 	-30 	-31 	-32 	-33
Dificid 	34 	22 	56 	83 	96 	179 	43 	25 	247 	-77 	-77 	-69 	-69
Lagevrio 	28 	5 	32 	102 	83 	185 	138 	57 	380 	-95 	-95 	-82 	-83
Diabetes
Januvia 	367 	258 	625 	549 	372 	921 	382 	302 	1,604 	-31 	-30 	-32 	-32
Janumet 	207 	171 	378 	247 	251 	498 	243 	199 	940 	-32 	-33 	-24 	-25
Other Pharmaceutical (7) 	774 	641 	1,416 	865 	703 	1,568 	1,004 	770 	3,340 	-9 	-9 	-10 	-11
ANIMAL HEALTH 	1,791 	1,775 	3,566 	1,588 	1,646 	3,234 	1,615 	1,505 	6,354 	8 	5 	10 	6
Livestock 	1,064 	1,041 	2,105 	924 	961 	1,885 	1,023 	987 	3,896 	8 	6 	12 	7
Companion Animal 	727 	734 	1,461 	664 	685 	1,349 	592 	518 	2,458 	7 	5 	8 	4
Other Revenues (8) 	146 	72 	218 	303 	110 	413 	50 	52 	515 	-35 	-34 	-47 	-6
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $161 million and $10 million in the first and second quarter of 2026,
respectively, and $44 million and $43 million in the first and second quarter of 2025, respectively.
(8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other
Revenues related to the receipt of milestone payments for out-licensed products were $132 million and $0 million in the first and second quarter of 2026, respectively, and $95 million and
$5 million in the first and second quarter of 2025, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,314 million and $2,361 million in the first and second quarter of 2026, respectively, and $2,607 million and $2,370 million in the first and second quarter of
2025, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in the Company's marketing territories.
5

-- 6 of 10 --

Global 	U.S. 	International
2Q 2026 	2Q 2025 	% Change 	2Q 2026 	2Q 2025 	% Change 	2Q 2026 	2Q 2025 	% Change
TOTAL SALES (1) 	$16,607 	$15,806 	5 	$9,367 	$8,836 	6 	$7,240 	$6,969 	4
PHARMACEUTICAL 	14,760 	14,050 	5 	8,827 	8,328 	6 	5,933 	5,722 	4
Oncology
Keytruda 	7,904 	7,956 	-1 	4,611 	4,749 	-3 	3,293 	3,207 	3
Keytruda Qlex 	463 	- 	395 	- 	68 	-
Alliance Revenue – Lynparza (2) 	365 	370 	-1 	167 	174 	-4 	198 	195 	2
Alliance Revenue – Lenvima (2) 	283 	265 	7 	194 	183 	6 	90 	83 	8
Welireg 	271 	162 	67 	214 	138 	55 	57 	24 	133
Alliance Revenue – Reblozyl (3) 	122 	107 	15 	98 	88 	11 	25 	19 	31
Vaccines (4)
Gardasil/Gardasil 9 	1,169 	1,126 	4 	542 	545 	-1 	626 	581 	8
ProQuad/M-M-R II/Varivax 	592 	609 	-3 	438 	481 	-9 	154 	128 	20
Capvaxive 	184 	129 	42 	138 	129 	7 	45 	-
Vaxneuvance 	148 	229 	-35 	69 	136 	-50 	80 	93 	-14
RotaTeq 	134 	121 	10 	84 	60 	39 	50 	61 	-18
Enflonsia 	2 	- 	2 	-
Cardiometabolic & Respiratory
Winrevair 	588 	336 	75 	522 	323 	61 	66 	12 	*
Ohtuvayre 	204 	- 	204 	-
Alliance Revenue - Adempas/Verquvo (5) 	126 	123 	3 	112 	108 	4 	14 	15 	-1
Adempas (6) 	78 	80 	-2 	78 	80 	-2
Infectious Diseases
Bridion 	497 	461 	8 	460 	411 	12 	37 	50 	-25
Prevymis 	295 	228 	29 	147 	115 	28 	148 	113 	31
Delstrigo 	101 	83 	21 	13 	14 	-7 	88 	70 	27
Zerbaxa 	77 	74 	4 	44 	45 	-3 	34 	29 	14
Isentress/Isentress HD 	60 	86 	-30 	36 	48 	-26 	24 	38 	-36
Dificid 	22 	96 	-77 	11 	83 	-87 	12 	13 	-11
Lagevrio 	5 	83 	-95 	1 	30 	-96 	3 	52 	-94
Diabetes
Januvia 	258 	372 	-31 	149 	216 	-31 	109 	155 	-30
Janumet 	171 	251 	-32 	28 	68 	-59 	143 	184 	-22
Other Pharmaceutical (7) 	641 	703 	-9 	150 	184 	-18 	489 	520 	-6
ANIMAL HEALTH 	1,775 	1,646 	8 	535 	499 	7 	1,240 	1,147 	8
Livestock 	1,041 	961 	8 	202 	190 	6 	838 	771 	9
Companion Animal 	734 	685 	7 	333 	309 	8 	402 	376 	7
Other Revenues (8) 	72 	110 	-35 	5 	9 	-44 	67 	100 	-33
*200% or greater
Table 3a
MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
SECOND QUARTER 2026
(AMOUNTS IN MILLIONS)
(UNAUDITED)
(6) Net product sales in the Company's marketing territories.
(7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $10 million and $43 million on a global basis in the
second quarter of 2026 and 2025, respectively.
(8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-
hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $0 million and $5 million on a global basis in the second
quarter of 2026 and 2025, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,361 million and $2,370 million on a global basis in the second quarter of 2026 and 2025, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
6

-- 7 of 10 --

Global 	U.S. 	International
June YTD
2026
June YTD
2025 	% Change
June YTD
2026
June YTD
2025 	% Change
June YTD
2026
June YTD
2025 	% Change
TOTAL SALES (1) 	$32,893 	$31,335 	5 	$18,532 	$17,359 	7 	$14,361 	$13,977 	3
PHARMACEUTICAL 	29,109 	27,688 	5 	17,338 	16,254 	7 	11,771 	11,434 	3
Oncology
Keytruda 	15,810 	15,161 	4 	9,210 	9,057 	2 	6,600 	6,104 	8
Keytruda Qlex 	590 	- 	501 	- 	89 	-
Alliance Revenue – Lynparza (2) 	706 	682 	4 	315 	319 	-1 	391 	363 	8
Alliance Revenue – Lenvima (2) 	539 	523 	3 	369 	368 	0 	170 	155 	9
Welireg 	470 	300 	57 	366 	261 	40 	103 	39 	166
Alliance Revenue – Reblozyl (3) 	270 	226 	20 	226 	189 	20 	45 	37 	21
Vaccines (4)
Gardasil/Gardasil 9 	2,238 	2,453 	-9 	1,027 	1,082 	-5 	1,211 	1,371 	-12
ProQuad/M-M-R II/Varivax 	1,130 	1,148 	-2 	847 	903 	-6 	283 	245 	16
Capvaxive 	325 	236 	38 	256 	235 	9 	69 	1 	*
Vaxneuvance 	350 	459 	-24 	192 	275 	-30 	158 	184 	-14
RotaTeq 	340 	349 	-3 	249 	225 	11 	91 	125 	-27
Enflonsia 	3 	- 	-1 	- 	4 	-
Cardiometabolic & Respiratory
Winrevair 	1,114 	615 	81 	999 	591 	69 	114 	24 	*
Ohtuvayre 	335 	- 	335 	-
Alliance Revenue - Adempas/Verquvo (5) 	235 	229 	3 	221 	205 	8 	14 	23 	-40
Adempas (6) 	156 	147 	6 	156 	147 	6
Infectious Diseases
Bridion 	969 	902 	7 	887 	789 	12 	82 	113 	-27
Prevymis 	568 	436 	30 	282 	217 	30 	285 	219 	30
Delstrigo 	176 	150 	17 	23 	29 	-21 	153 	121 	26
Zerbaxa 	159 	145 	10 	95 	87 	9 	64 	57 	12
Isentress/Isentress HD 	119 	176 	-32 	71 	99 	-29 	49 	77 	-37
Dificid 	56 	179 	-69 	35 	155 	-77 	21 	24 	-10
Lagevrio 	32 	185 	-82 	18 	66 	-73 	15 	119 	-87
Diabetes
Januvia 	625 	921 	-32 	401 	561 	-29 	224 	360 	-38
Janumet 	378 	498 	-24 	96 	133 	-28 	283 	366 	-23
Other Pharmaceutical (7) 	1,416 	1,568 	-10 	318 	408 	-22 	1,097 	1,160 	-5
ANIMAL HEALTH 	3,566 	3,234 	10 	1,054 	1,001 	5 	2,512 	2,233 	12
Livestock 	2,105 	1,885 	12 	414 	384 	8 	1,691 	1,501 	13
Companion Animal 	1,461 	1,349 	8 	640 	617 	4 	821 	732 	12
Other Revenues (8) 	218 	413 	-47 	140 	104 	35 	78 	310 	-75
*200% or greater
Table 3b
MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
JUNE YEAR-TO-DATE 2026
(AMOUNTS IN MILLIONS)
(UNAUDITED)
(6) Net product sales in the Company's marketing territories.
(7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $171 million and $87 million on a
global basis for June YTD 2026 and 2025, respectively.
(8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including
revenue-hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $132 million and $100 million on
a global basis for June YTD 2026 and 2025, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $4,675 million and $4,977 million on a global basis for June YTD 2026 and 2025, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
7

-- 8 of 10 --

MERCK & CO., INC., RAHWAY, N.J., USA
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2026 	2025 	% Change
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	2Q 	June YTD
TOTAL PHARMACEUTICAL 	$14,349 	$14,760 	$29,109 	$13,638 	$14,050 	$27,688 	$15,611 	$14,843 	$58,142 	5 	5
United States 	8,512 	8,827 	17,338 	7,927 	8,328 	16,254 	9,493 	8,662 	34,409 	6 	7
% Pharmaceutical Sales 	59.3% 	59.8% 	59.6% 	58.1% 	59.3% 	58.7% 	60.8% 	58.4% 	59.2%
Europe (1) 	2,725 	2,801 	5,525 	2,384 	2,551 	4,935 	2,675 	2,839 	10,449 	10 	12
% Pharmaceutical Sales 	19.0% 	19.0% 	19.0% 	17.5% 	18.2% 	17.8% 	17.1% 	19.1% 	18.0%
Latin America 	624 	636 	1,260 	589 	654 	1,243 	691 	644 	2,578 	-3 	1
% Pharmaceutical Sales 	4.3% 	4.3% 	4.3% 	4.3% 	4.7% 	4.5% 	4.4% 	4.3% 	4.4%
Asia Pacific (other than China and Japan) 	569 	636 	1,205 	535 	609 	1,144 	593 	586 	2,323 	5 	5
% Pharmaceutical Sales 	4.0% 	4.3% 	4.1% 	3.9% 	4.3% 	4.1% 	3.8% 	4.0% 	4.0%
Japan 	535 	558 	1,093 	651 	604 	1,255 	693 	684 	2,632 	-8 	-13
% Pharmaceutical Sales 	3.7% 	3.8% 	3.8% 	4.8% 	4.3% 	4.5% 	4.4% 	4.6% 	4.5%
Eastern Europe/Middle East/Africa 	413 	408 	821 	435 	451 	886 	365 	348 	1,598 	-10 	-7
% Pharmaceutical Sales 	2.9% 	2.8% 	2.8% 	3.2% 	3.2% 	3.2% 	2.3% 	2.3% 	2.7%
China 	353 	368 	721 	668 	407 	1,075 	377 	364 	1,816 	-9 	-33
% Pharmaceutical Sales 	2.5% 	2.5% 	2.5% 	4.9% 	2.9% 	3.9% 	2.4% 	2.5% 	3.1%
Canada 	137 	154 	291 	125 	135 	261 	134 	153 	547 	14 	12
% Pharmaceutical Sales 	1.0% 	1.0% 	1.0% 	0.9% 	1.0% 	0.9% 	0.9% 	1.0% 	0.9%
Other 	481 	372 	855 	324 	311 	635 	590 	563 	1,790 	20 	35
% Pharmaceutical Sales 	3.3% 	2.5% 	2.9% 	2.4% 	2.1% 	2.4% 	3.9% 	3.8% 	3.2%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
2Q26 	2Q25
June
YTD 2026
June YTD
2025
Interest income 	(35)	$ 	(69)	$ 	(70)	$ 	(178)	$
Interest expense 	525 	305 	1,004 	618
Exchange losses 	37 	78 	75 	167
Income from investments in equity securities, net (1) (242) 	(100) 	(411) 	(189)
Net periodic defined benefit plan (credit) cost other than service cost 	(127) 	(152) 	(262) 	(300)
Other, net 	(59) 	(69) 	(99) 	(161)
Total 	99	$ 	(7)	$ 	237	$ 	(43)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment
funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from
ownership interests in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC., RAHWAY, N.J., USA
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --